证券代码：300887 证券简称：谱尼测试 公告编号：2024-074 谱尼测试集团股份有限公司 内容详见同日刊登于中国证监会指定创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）的相关公告。 表决结果：3 票同意，0 票反对，0 票弃权，审议通过本项议案。 一、监事会会议召开情况 谱尼测试集团股份有限公司（以下简称"公司"）第五届监事会第十四次 会议于 2024 年 10 月 23 日下午在北京市海淀区中关村环保科技示范园锦带路 66 号院 1 号楼谱尼测试大厦 207 会议室以现场表决的方式召开，本次会议的通知已 于 2024 年 10 月 18 日以专人送达的方式发出。会议由监事会主席吴俊霞女士召 集和主持，会议应出席监事 3 人，实际出席监事 3 人。本次会议的召集、召开符 合《公司法》和《公司章程》的有关规定。 二、监事会会议审议情况 出席会议的监事对各项议案进行了认真审议并做出了如下决议： （一）审议通过《关于〈2024 年第三季度报告〉的议案》 经审核，监事会认为：董事会编制和审核公司《2024 年第三季度报告》符 合法律、行政法规和中国证监会的规定，报告内容真实 ...

Revenue and Profitability - Revenue for Q3 2024 was CNY 395,340,477.77, a decrease of 30.77% year-over-year[2] - Net profit attributable to shareholders was a loss of CNY 62,769,423.34, down 621.24% compared to the same period last year[2] - Operating profit for the year-to-date was a loss of CNY 236,967,567.47, a decline of 286.83% compared to the same period last year[6] - Total operating revenue for the current period is ¥1,123,414,813.30, a decrease of 36.2% compared to ¥1,758,239,802.93 in the previous period[15] - Net profit for the current period is -¥232,284,161.44, compared to a net profit of ¥106,862,369.46 in the previous period, indicating a significant loss[16] - Basic earnings per share for the current period is -0.4288, compared to 0.1931 in the previous period, indicating a decline in profitability[17] - The total comprehensive income for the current period is -¥232,280,901.65, compared to ¥106,856,136.00 in the previous period, indicating a substantial decline[17] Cash Flow and Financial Activities - The net cash flow from operating activities for the year-to-date was a negative CNY 116,167,781.29, representing a decline of 219.68% year-over-year[2] - Cash received from sales decreased by 35.56% to ¥1,153,939,674.76 compared to ¥1,790,621,509.56 in the same period last year[7] - Cash flow from operating activities shows a net outflow of -¥116,167,781.29, contrasting with a net inflow of ¥97,066,416.16 in the previous period[18] - Total cash inflow from financing activities increased by 31.74% to ¥216,808,967.28 compared to ¥164,568,545.61 in the previous year[7] - The net cash flow from financing activities was -19,153,361.63 CNY, an improvement compared to -177,652,644.69 CNY in the previous quarter[19] Assets and Liabilities - Total assets decreased by 8.77% from the end of the previous year, amounting to CNY 3,957,737,675.69[2] - The company's equity attributable to shareholders decreased by 7.55% to CNY 3,194,739,815.79 compared to the end of the previous year[2] - Total liabilities decreased from CNY 870,630,239.33 to CNY 751,418,088.27, reflecting a reduction of approximately 13.7%[14] - The total current assets decreased from CNY 2,307,439,472.52 to CNY 1,985,629,926.19, reflecting a decline of about 13.9%[12] - The total non-current assets decreased from CNY 2,030,617,028.66 to CNY 1,972,107,749.50, a decline of approximately 2.9%[13] Cash and Equivalents - Cash and cash equivalents decreased by 44.52% to CNY 343,846,858.64, primarily due to reduced sales collections[5] - Cash and cash equivalents dropped significantly from CNY 619,767,851.89 to CNY 343,846,858.64, a decrease of about 44.5%[12] - The ending balance of cash and cash equivalents was 339,540,695.93 CNY, down from 533,163,319.10 CNY in the previous quarter[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,848[8] - The largest shareholder, Song Wei, holds 44.83% of the shares, totaling 244,645,596[8] Other Financial Metrics - The company reported a total of CNY 4,667,724.76 in non-recurring gains and losses for the current period[3] - Interest income decreased by 56.64% to CNY 4,040,661.77, attributed to reduced funds and lower deposit rates[6] - The company reported a significant increase in other income, up 340.20% to ¥1,156,543.53, mainly from penalties and insurance claims[7] - The company’s tax expense was negative at -¥6,050,360.73, reflecting operational losses and the recognition of deferred tax assets[7] - The company reported a decrease in research and development expenses to ¥120,619,470.24, down from ¥142,106,527.87, reflecting a 15.1% reduction[15] Investment Activities - Cash outflow for purchasing fixed assets decreased by 67.41% to ¥149,292,374.03 from ¥458,083,893.97[7] - The cash paid for the acquisition of fixed assets, intangible assets, and other long-term assets was 149,292,374.03 CNY, significantly lower than 458,083,893.97 CNY in the previous quarter[19] Audit and Reporting - The third quarter report was not audited, indicating potential areas for further scrutiny in financial reporting[19]

证券代码：300887 证券简称：谱尼测试 公告编号：2024-073 谱尼测试集团股份有限公司 第五届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 谱尼测试集团股份有限公司（以下简称"公司"）第五届董事会第十五次 会议于 2024 年 10 月 23 日下午在北京市海淀区中关村环保科技示范园锦带路 66 号院 1 号楼谱尼测试大厦 207 会议室以现场表决的方式召开。本次会议的通知已 于 2024 年 10 月 18 日以专人送达的方式发出。会议由董事长宋薇女士召集和主 持，会议应出席董事 6 人，实际出席董事 6 人，公司监事列席了会议。本次会议 的召集、召开符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 出席会议的董事对各项议案进行了认真审议并做出了如下决议： （一）审议通过《关于〈2024 年第三季度报告〉的议案》 经审议，董事会认为：公司《2024 年第三季度报告》符合法律、行政法规、 中国证券监督管理委员会和深圳证券交易所的相关规定，内容真实、准确、完整， 不存在任何虚假记载、误导性陈述或重大遗漏。 ...

证券代码：300887 证券简称：谱尼测试 公告编号：2024-072 谱尼测试集团股份有限公司 1、股东减持股份情况 | 大宗交易 | 2024/7/24 | 至 | - | - | - | | --- | --- | --- | --- | --- | --- | | | 2024/10/14 | | | | | | 合计 | | | | 624,893 | 0.11% | 2、本次减持前后持股变动情况： | 股东名称 | 股份性质 | 变动前持股情况 | | 变动后持股情况 | | | --- | --- | --- | --- | --- | --- | | | | 股份数 | 占总股 | 股份数 | 占总股 | | | | （股） | 本比例 | （股） | 本比例 | | 谱泰中瑞 | 合计持有股份 | 21,546,000 | 3.95% | 20,921,107 | 3.83% | | | 其中：无限售条件股份 | 21,546,000 | 3.95% | 20,921,107 | 3.83% | | | 有限售条件股份 | 0.00 | - | 0.00 | - | | 谱瑞恒祥 | 合计持 ...

证券代码：300887 证券简称：谱尼测试 谱尼测试集团股份有限公司投资者关系活动记录表 编号：2024-002 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------------|-------------------------------------|--------------------------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | □特定对象调研 | 分析师会议 | | | | | | | | | 投资者关系活动 | □媒体采访 □新闻发布会 | ☑ 业绩说明会 路演活动 | | | | | | | | | 类别 | 现场参观 | | | | | | | | | | | 其他（电话会议） | | | | | | | | | | 活动参与人员 | 详见附件 | | | | | | | | | | 时间 | 2024 年 8 月 29 日-9 月 | 20 日 | | | | | ...

华泰联合证券有限责任公司 关于谱尼测试集团股份有限公司 2024 年半年度持续督导跟踪报告 | 保荐人名称：华泰联合证券有限责任公司 | 被保荐公司简称：谱尼测试集团股份有限公司 | | --- | --- | | 保荐代表人姓名：刘晓宁 | 联系电话：010-56839300 | | 保荐代表人姓名：王禹 | 联系电话：010-56839300 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 无 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括 但不限于防止关联方占用公司资源的制度、 | | | | 是 | | 募集资金管理制度、内控制度、内部审计制 | | | 度、关联交易制度） | | | | 除"二、保荐人发现公司存在的问题及采取的 | | （2）公司是否有效执行相关规章制度 | 措施"之"1.信息披露"所述不规范情形外， | | | 公司有效执行相关规章制度 | | 3.募集资 ...

Investment Rating - The report maintains an "Accumulate" rating for the company [1] Core Views - The company is experiencing short-term pressure on performance due to strategic adjustments and a weak downstream market in biomedicine, with expectations for profit recovery in the future [2][3] - The company has shifted its focus towards enterprise clients, impacting new order acquisition, and is currently undergoing a strategic transformation [2] - The company is investing in new laboratory facilities across multiple regions to enhance its comprehensive testing capabilities [3] Financial Performance Summary - In the first half of 2024, the company achieved total revenue of 730 million yuan, a year-on-year decrease of 39%, and a net profit attributable to shareholders of -170 million yuan, a year-on-year decline of 284% [2] - The gross profit margin for the first half of 2024 was 28.8%, down 15.7 percentage points year-on-year, while the net profit margin was -23.6%, down 31.5 percentage points year-on-year [3] - The company has adjusted its earnings forecasts for 2024-2026 to 0.08 billion yuan (previously 3.0 billion), 1.7 billion yuan (previously 3.8 billion), and 2.7 billion yuan (previously 4.6 billion), respectively [3] Business Segment Performance - Revenue from the life sciences and environmental health segment was 500 million yuan, a decrease of 45% year-on-year, while revenue from the automotive and other consumer goods segment was 130 million yuan, an increase of 4% year-on-year [2] - The company is currently facing challenges in its traditional business client structure and is experiencing losses due to fixed costs from newly established laboratories [2][3] Market Data - The company's closing price is 6.46 yuan, with a market capitalization of approximately 3.53 billion yuan [4] - The price-to-earnings ratio (P/E) based on the latest diluted earnings per share is projected to be 433.85 for 2024 [3][12]

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2024, representing a year-on-year increase of 15%[8]. - The net profit attributable to shareholders for the same period was RMB 80 million, up 20% compared to the previous year[8]. - Future guidance indicates a projected revenue growth of 18% for the full year 2024[8]. - The company's operating revenue for the reporting period was ¥728,074,335.53, a decrease of 38.67% compared to the same period last year[14]. - The net profit attributable to shareholders was -¥171,373,267.55, representing a decline of 283.62% year-on-year[14]. - The net cash flow from operating activities was -¥86,273,322.94, down 158.67% from the previous year[14]. - The company's gross profit margin for the life sciences and health environmental segment was 20.54%, down 21.43% year-on-year, with revenue declining by 45.34%[53]. - The company reported a significant focus on cash dividends, with a minimum cash dividend ratio of 80% during mature stages without major capital expenditure arrangements[120]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 25% growth in that region by the end of 2025[8]. - The company is exploring acquisition opportunities to enhance its service offerings and market share[8]. - A strategic acquisition of a local competitor is expected to be finalized by Q4 2024, which will enhance the company's service offerings[115]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share by the end of 2025[114]. Research and Development - The company is investing RMB 30 million in R&D for new technologies related to environmental testing[8]. - Research and development expenses amounted to ¥85,110,921.08, down 17.04% from ¥102,597,481.82, mainly due to reduced sales collections[52]. - The company launched an AI target prediction and virtual screening project in collaboration with the Shanghai Institute of Materia Medica, enhancing drug quality assurance in veterinary medicine[46]. - Research and development expenses for the first half of 2024 were CNY 15.47 million, down from CNY 20.63 million in the same period of 2023, indicating a reduction of approximately 25.5%[170]. Operational Challenges - The management highlighted potential risks including regulatory changes and market competition, with strategies in place to mitigate these risks[2]. - The company is facing risks from intensified market competition, particularly from state-owned and foreign testing institutions, which may impact its operational performance[73]. - The company reported a decline in overall gross profit due to a shift in customer structure and increased competition in the biopharmaceutical CRO/CDMO sector, leading to losses[45]. - The company acknowledges the potential impact of adverse changes in industry policies and standards on its business development[73]. Corporate Governance and Shareholder Relations - The company has a strong commitment to protecting the rights of shareholders and creditors, ensuring transparency and communication through various channels[100]. - The company has established a "Quality Return Dual Improvement" action plan to enhance investor confidence and maintain long-term sustainable development[78]. - The company held two temporary shareholder meetings and one annual shareholder meeting in 2024, with investor participation rates of 64.39%, 64.38%, and 64.50% respectively[83][84][85]. - The company plans to implement a shareholder dividend return plan for the next three years (2024-2026) to ensure stable profit distribution[80]. Environmental and Social Responsibility - The company has implemented measures to reduce carbon emissions, including promoting green office practices and encouraging employees to use public transportation[98]. - The company emphasizes social responsibility, actively participating in public welfare and charity initiatives while ensuring compliance with relevant laws and regulations[99]. - PONY Group actively participated in charitable activities, donating materials to various charitable organizations and welfare institutions across multiple cities, including Shenzhen and Shanghai[106]. - The company has established a comprehensive environmental protection management system, including regulations and guidelines for energy management and carbon emissions[104]. Financial Management and Investments - The total amount of funds raised by the company was RMB 1,227,843,967.82 after deducting fees[60]. - The company has cumulatively invested RMB 70,598.31 million of the raised funds as of the reporting period[60]. - The company reported a fair value change of financial assets amounting to RMB 532,036,981.91 at the end of the reporting period[55]. - The company has a long-term commitment to normal operations regarding share repurchase measures[119]. Compliance and Regulatory Matters - The company has maintained compliance with the accounting standards set by the Ministry of Finance, ensuring accurate financial reporting[192]. - The company has not encountered any issues or other circumstances regarding the use of raised funds[65]. - The company has not reported any changes in the board of directors or supervisory board during the reporting period[85]. - The company has not engaged in any significant related party transactions during the reporting period[131].

证券代码：300887 证券简称：谱尼测试 公告编号：2024-064 谱尼测试集团股份有限公司 第五届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 谱尼测试集团股份有限公司（以下简称"公司"）第五届董事会第十四次 会议于 2024 年 8 月 28 日下午在北京市海淀区中关村环保科技示范园锦带路 66 号院 1 号楼谱尼测试大厦 207 会议室以现场表决的方式召开。本次会议的通知已 于 2024 年 8 月 16 日以专人送达的方式发出。会议由董事长宋薇女士召集和主持， 会议应出席董事 6 人，实际出席董事 6 人，公司监事列席了会议。本次会议的召 集、召开符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 出席会议的董事对各项议案进行了认真审议并做出了如下决议： （一）审议通过《关于〈2024 年半年度报告〉全文及其摘要的议案》 募集资金存放和使用违规的情形，不存在变相改变募集资金投向和损害股东利益 的情况；公司编制的《2024 年半年度募集资金存放与使用情况的专项报告》内 容真实、准确、 ...

谱尼测试集团股份有限公司2024年半年度 非经营性资金占用及其他关联资金往来情况汇总表 谱尼测试集团股份有限公司2024年半年度 非经营性资金占用及其他关联资金往来情况汇总表 | | | | | | | | | | 单位：万元 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 上市公司的子公司 | 内蒙古谱尼测试技 | 全资子公司 | 应收账款 | 518.32 | 141.94 | 261.87 | | 398.39 | 经营往来 | 经营性往来 | | 及其附属企业 | 术有限公司 | | | | | | | | | | | 上市公司的子公司 | 郑州国准检测技术 | 全资子公司 | 应收账款 | 273.94 | 20.77 | | - | 294.71 | 经营往来 | 经营性往来 | | 及其附属企业 | 有限公司 | | | | | | | | | | | 上市公司的子公司 | 武汉谱尼科技有限 公司 | 全资子公司 | 应收账款 | 268.57 | 47.62 | | - | 316.19 | 经 ...